Sep 10, 2020 / 07:20PM GMT
Neena Marie Bitritto-Garg - Citigroup Inc., Research Division - VP & Analyst
All right. Hi, everyone. Thank you so much for joining the Citi's 15th Annual Biopharma Conference. My name is Neena Bitritto-Garg. I'm one of the mid-cap biotech analyst here at Citi.
So for our next panel, I'm very pleased to be joined by CEOs from Denali, Passage Bio and Prevail Therapeutics. So from Denali, we have Ryan Watts. From Passage Bio, we have Bruce Goldsmith. And from Prevail, we have Asa -- sorry, I apologize, Abeliovich. And we're going talk today about neurodegenerative diseases and some of the emerging and new kind of therapeutic modalities and mechanisms that companies are working on to combat neurodegenerative disease.
So to start off, I'd like to give everyone the opportunity to kind of just give a quick 1-minute intro kind of on the company, on -- and what you're working on right now. So if we want to start with -- maybe with Asa, and then we can go to Bruce and then Ryan.
Asa Abeliovich - Prevail Therapeutics Inc. - Founder, President, CEO
Passage Bio Inc, Denali Therapeutics, and Prevail Therapeutics at Citi BioPharma Conference (Virtual) - Panel Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers